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Background: Chronic mucous hypersecretion (CMH) contributes to COPD exacerbations and increased risk for lung
cancer. Because methylation of gene promoters in sputum has been shown to be associated with lung cancer risk,
we tested whether such methylation was more common in persons with CMH.
Methods: Eleven genes commonly silenced by promoter methylation in lung cancer and associated with cancer risk
were selected. Methylation specific PCR (MSP) was used to profile the sputum of 900 individuals in the Lovelace
Smokers Cohort (LSC). Replication was performed in 490 individuals from the Pittsburgh Lung Screening Study (PLuSS).
Results: CMH was significantly associated with an overall increased number of methylated genes, with SULF2
methylation demonstrating the most consistent association. The association between SULF2 methylation and CMH
was significantly increased in males but not in females both in the LSC and PLuSS (OR = 2.72, 95% CI = 1.51-4.91,
p = 0.001 and OR = 2.97, 95% CI = 1.48-5.95, p = 0.002, respectively). Further, the association between methylation
and CMH was more pronounced among 139 male former smokers with persistent CMH compared to current
smokers (SULF2; OR = 3.65, 95% CI = 1.59-8.37, p = 0.002).
Conclusions: These findings demonstrate that especially male former smokers with persistent CMH have markedly
increased promoter methylation of lung cancer risk genes and potentially could be at increased risk for lung
cancer.
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Lung cancer genesBackground
Chronic obstructive pulmonary disorder (COPD) is pre-
dicted to become the third leading cause of death
worldwide by 2020 [1]. Prevalence is increasing both in
developing and developed countries as a result of tobacco
consumption [2,3], environmental exposures such as pollu-
tion and biomass fuel smoke [4,5] and the growing elderly
population [6]. Clinically, COPD is defined by the presence
of poorly reversible airflow obstruction, although this defin-
ition simplifies the complex causes and manifestations of
the disease [7]. Chronic mucous hypersecretion (CMH),* Correspondence: ytesfaig@lrri.org
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stated.characterized by persistent mucous cell metaplasia in the
epithelial layer and submucosal glands of the respiratory
tract, is a clinically important COPD phenotype [8]. CMH
leads to worse respiratory symptoms, greater susceptibility
to respiratory infections, more frequent COPD exacerba-
tions, and increased risk of mortality [9-14].
Numerous publications, and two recent meta-analyses,
have determined that prior CMH significantly increases
the risk for later lung cancer [15,16]. While smoking
clearly contributes to both diseases, analyses controlling
for smoking have demonstrated that the association
between lung cancer and prior CMH is at least partially
independent of smoking [15,16]. It is therefore plausible
that CMH and lung cancer have some shared molecular
pathology. Previous case–control studies of incident lungtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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demonstrated that promoter methylation of these genes is
associated with lung cancer risk [17,18].
The goal of this study was to determine whether there
was any association between CMH and prevalence of
methylation of promoters in lung cancer-predictive
genes in sputum DNA of smokers. Therefore, methyla-
tion specific PCR (MSP) was used to assess promoter
methylation of eleven genes in sputum samples of
smokers from the Lovelace Smokers Cohort (LSC). Rep-
lication was performed in smokers from the Pittsburgh
Lung Screening Study (PLuSS).
Methods
Study populations
This study is approved by the Western Institutional Review
Board (Olympia, WA; #20031684) and all subjects signed in-
formed consent for their participation. The catchment area
for the LSC was the Albuquerque, NM metropolitan area,
comprising a population of approximately 850,000 persons.
Inclusion criteria for entry into the current study were age
40 to 75 years, current or former cigarette smoking (with a
minimum of 10 pack-years) upon entry into the study, and
ability to understand English. The LSC disproportionately
enrolled women ever-smokers to study the susceptibility to
the development of smoking-related lung diseases since
women are underrepresented in most such studies in the
United States. Detailed characteristics of the LSC have been
described elsewhere [19,20]. From the LSC cohort, 311
non-Hispanic white (NHW) individuals meeting the criteria
for CMH were included along with 589 NHW current or
former smoking controls. Current and former smoking was
assessed by self-report at baseline concurrent with sputum
sampling. Former smokers are those who have stopped
smoking for at least 2 years prior to self-report.
Study participants for the replication cohort were from
the Pittsburgh Lung Screening Study (PLuSS), a volun-
teer cohort established to investigate lung cancer bio-
markers in an at-risk population of smokers which has
previously been described [21,22]. From the total cohort
(n = 3638), 490 NHW individuals (183 men and 307
women) had information allowing classification with
respect to chronic mucous hypersecretion and had pro-
vided sputum for DNA isolation. Spirometric testing
procedures have previously been described for both the
PLuSS and the LSC [19,21].
Because a unifying definition for CMH was not available
in both cohorts two criteria were used to define CMH: In
the LSC, CMH was defined as present in participants that
had self-reported cough productive of phlegm for at least
3 months per year for at least 2 consecutive years (ie. the
standard definition of chronic bronchitis). In the PLuSS,
CMH was defined as self-reported cough productive of
phlegm as assessed by both a first and second questionnaire(with a median questionnaire interval of 3.5 years), and
self-reported cough producing phlegm for “most days a
week” or “several days a week” in the past year, as assessed
by the second questionnaire.
Methylation specific PCR
Nested MSP assays were used to detect methylation of
cytosines at cytosine-phosphate-guanine sites in DNA
recovered from the sputum samples, as previously de-
scribed [23,24]. We studied the promoter methylation of
a panel of eleven tumor suppressor genes with previ-
ously identified roles in predicting lung cancer risk
[17,18]. These genes included PCDH-20 (Protocadherin);
SULF-2 (6-O-endosulfatase 2); GATA binding protein-4
and −5 transcription factors; PAX-5α and PAX-5β
(paired box protein transcription factors); p16; MGMT
(O (6)-methylguanine-DNA methyltransferase); DAPK
(Death-associated protein kinase); DAL-1 (Differentially
expressed in adenocarcinoma of the lung); and JPH-3
(Junctophilin). Methylation by this technique was scored
positive or negative, as previously described [18].
Statistical analysis
Chi-square and Fisher’s exact tests were used for the
univariate analyses of categorical variables, while two-
sample t-tests and Kruskal-Wallis tests were used for
continuous variables. For multivariable analyses of CMH,
logistic regression was performed. Predictors included
gene specific methylation prevalence, and also total
methylation (continuous variable representing the sum
of genes methylated within an individual). Additional
predictors included age, education (dichotomized as at
least high school or less than high school education),
COPD status, sex, pack-years smoking, and current
smoking status. When the LSC and PLuSS were com-
bined for analyses adjustment for cohort was included.
Model fitting iterations were performed with the R
package glmulti using the small sample size corrected
Akiake information criterion to determine best-fitting
models [25]. All statistical analyses were performed in R
version 2.12.0 or SAS version 9.2.
Results
CMH is associated with higher prevalence of gene
promoter methylation in smokers
The initial study was conducted in 900 NHW current
and former smokers from the LSC with available sputum
methylation data. At time of sputum collection, there
were 311 smokers with and 589 smokers without CMH.
In unadjusted analysis, prevalence of SULF2 methylation
was significantly higher in those with CMH than without
CMH (39 % and 30 % respectively, p < 0.01, Table 1). A
replication study was performed in the PLuSS, comprised
of 140 smokers with and 350 smokers without CMH,
Table 1 Select variables by CMH status in the LSC
LSC Total CMH No CMH
n = 900 (100.0) n = 311 (100.0) n = 589 (100.0)
Characteristic n or mean (%) or (SD) n or mean (%) or (SD) n or mean (%) or (SD) p value
Female 673 (74.8) 222 (71.3) 451 (76.6) 0.088
Baseline age 55.9 (9.6) 55.1 (9.8) 56.3 (9.4) 0.067
Education > = HS* 663 (73.7) 207 (66.6) 456 (77.4) <0.001
Obese 278 (30.9) 93 (29.9) 185 (31.4) 0.642
Pack years 41.1 (20.9) 44.2 (21.8) 39.5 (20.2) 0.001
Baseline smoker 494 (55.6) 236 (76.4) 258 (44.6) <.0001
Baseline COPD 281 (31.2) 123 (39.6) 158 (26.8) <.0001
Total methylation 2.47 (2.12) 2.66 (2.22) 2.37 (2.06) 0.057
PCDH20 333 (37.0) 125 (40.2) 208 (35.3) 0.149
SULF2 299 (33.2) 122 (39.2) 177 (30.1) 0.005
GATA4 348 (38.7) 125 (40.2) 223 (37.9) 0.495
PAX5A 138 (15.3) 46 (14.8) 92 (15.6) 0.743
p16 154 (17.1) 61 (19.6) 93 (15.8) 0.147
MGMT 249 (27.7) 87 (28.0) 162 (27.5) 0.881
DAPK 153 (17.0) 54 (17.4) 99 (16.8) 0.833
GATA5 152 (16.9) 55 (17.7) 97 (16.5) 0.643
PAX5B 90 (10.0) 30 (9.7) 60 (10.2) 0.797
DAL1 71 (7.9) 27 (8.7) 44 (7.4) 0.521
JPH3 229 (25.4) 91 (29.3) 138 (23.4) 0.056
*High school.
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tion was significantly higher in those with CMH than
those without CMH (40 % and 26 % respectively, p < 0.01,
Table 2).
In adjusted analysis in the LSC, total methylation (defined
as the cumulative prevalence of methylation for all 11
genes; see Methods) was significantly higher in smokers
with CMH, as was methylation prevalence of SULF2,
JPH3, and PCDH20 (p < 0.05, all analyses) (Table 3).
Similarly, adjusted analysis in the PLuSS showed that
total methylation was significantly higher in those with
CMH, as was methylation prevalence of SULF2, p16,
and PCDH20 (p < 0.05, all analyses) (Table 3).
Analyses combining the two cohorts were also per-
formed. In both unadjusted (Additional file 1: Table S1)
and adjusted (Table 3) analysis in the combined cohorts,
total methylation was higher in those with CMH than
in those with an absence of CMH, as was methylation
prevalence of SULF2, JPH3, p16 and PCDH20 (p < 0.01,
all analyses). Additional factors associated with CMH
were younger age, less education, having COPD, greater
pack years, and current smoking (p < 0.01, all analyses,
Additional file 1: Table S1). Additional modeling was
performed that included two-way interaction terms for
baseline COPD, pack years and methylation, total orindividual gene for the combined cohort of LSC and
PLuSS cohorts. These interaction terms were not sig-
nificant for total methylation, Sulf-2, or PCDH20, each
of which showed significant association with CMH
within the LSC, the PluSS cohort, and the combination
of both cohorts. These findings suggest methylation is
an independent risk for CMH.
The association between CMH and gene promoter
methylation is stronger in males
Univariate analysis revealed factors that were associated
with higher methylation prevalence, which include male
sex (p < 0.001) (Additional file 1: Table S2). Because of
the observed sex differences in methylation prevalence,
sex stratified analyses were performed in males and
females. Total methylation was significantly associated
with CMH in males in both the LSC and PLuSS cohorts
(p < 0.01, both analyses) and when analysis was per-
formed for the combined cohort (p < 0.001) (Table 4).
When individual genes were analyzed in males, SULF2,
p16, and JPH3 were significantly associated in the LSC
(p < 0.05, all analyses), while SULF2 and PCDH20 were
significant in the PLuSS (p < 0.05). In the combined
cohort, the prevalence of SULF2, JPH3, PCDH20, and
p16 methylation were all significantly higher in males with
Table 2 Select variables by CMH status in the PLuSS
PLuSS Total CMH No CMH
n = 490 (100.0) n = 140 (100.0) n = 350 (100.0)
Characteristic n or mean (%) or (SD) n or mean (%) or (SD) n or mean (%) or (SD) p value
Female 307 (62.7) 90 (64.3) 217 (62.0) 0.637
Baseline age 60.3 (6.4) 59.5 (6.1) 60.6 (6.5) 0.075
Education > = HS* 474 (96.7) 134 (95.7) 340 (97.1) 0.422
Obese 158 (32.2) 45 (32.1) 113 (32.3) 0.976
Pack Years 55.9 (20.1) 59 (19.1) 54.6 (20.4) 0.029
Baseline smoker 335 (68.4) 113 (80.7) 222 (63.4) <0.001
Baseline COPD 238 (48.6) 81 (57.9) 157 (44.9) 0.009
Total methylation 2 (1.84) 2.26 (2.04) 1.9 (1.75) 0.052
PCDH20 135 (27.6) 47 (33.6) 88 (25.1) 0.059
SULF2 147 (30.0) 56 (40.0) 91 (26.0) 0.002
GATA4 166 (33.9) 47 (33.6) 119 (34.0) 0.928
PAX5A 68 (13.9) 23 (16.4) 45 (12.9) 0.302
p16 92 (18.8) 32 (22.9) 60 (17.1) 0.143
MGMT 123 (25.1) 34 (24.3) 89 (25.4) 0.792
DAPK 75 (15.3) 21 (15.0) 54 (15.4) 0.905
GATA5 64 (13.1) 18 (12.9) 46 (13.1) 0.932
PAX5B 33 (6.7) 9 (6.4) 24 (6.9) 0.864
DAL1 37 (7.6) 14 (10.0) 23 (6.6) 0.194
JPH3 41 (8.4) 15 (10.7) 26 (7.4) 0.235
*High school.
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analyses). Although the number of female participants
was higher for both cohorts, in females, no significant
associations were found for the individual cohort analyses,
although higher SULF2 methylation prevalence was ob-
served in analysis of the combined cohorts (p < 0.05).
The association between CMH and gene promoter
methylation is stronger in former smokers
Current smoking status and pack years were controlled
for in adjusted analyses (Tables 3 and 4); however, residualTable 3 Odds ratios for CMH in adjusted* analyses
LSC n = 900
Exposure variable OR (95 % CL) p value OR
Total methylation 1.09*** (1.02, 1.17) 0.014 1.15
SULF2 1.68 (1.23, 2.30) 0.001** 2.14
p16 1.43 (0.97, 2.11) 0.067 1.69
JPH3 1.45 (1.04, 2.03) 0.031 1.70
PCDH20 1.40 (1.03, 1.90) 0.033 1.73
Each row represents a separate adjusted model.
LSC: CMH (n = 311) and no CMH (n = 589); PLuSS CMH (n = 140) and no CMH (n = 3
*Additional adjustors include age, sex, education, COPD, current smoking, pack yea
**Bonferroni adjusted significance threshold is p < 0.0042.
***Represents the odds ratio increase for each additional gene methylated.confounding remains a possibility, given that current
smoking strongly influences CMH status (Tables 1 and 2).
Therefore, stratified analyses were performed in current
and former smokers. Adjusted stratified analysis revealed
for both the LSC and PLuSS that total methylation was
significantly higher in those with CMH who were former
smokers (p < 0.05, all analyses) (Table 5). Although the
number of current smokers was greater in both cohorts,
in current smokers total methylation was not significantly
associated with CMH in either cohort or the combined
analysis. In general, the associations between methylationPLuSS n = 490 Combined n = 1390
(95 % CL) p value OR (95 % CL) p value
(1.03, 1.29) 0.014 1.11 (1.04, 1.18) 0.001**
(1.38, 3.31) 0.001** 1.79 (1.39, 2.31) <.0001**
(1.01, 2.83) 0.045 1.54 (1.14, 2.10) 0.006
(0.83, 3.48) 0.149 1.53 (1.13, 2.08) 0.006
(1.10, 2.73) 0.018 1.47 (1.14, 1.90) 0.003**
50).
rs, and cohort (for combined analysis); CMH as outcome.
Table 4 Odds ratios for CMH in sex stratified adjusted* analyses
Males LSC n = 227 PLuSS n = 183 Combined n = 410
Exposure variable OR (95% CL) p value OR (95% CL) p value OR (95% CL) p value
Total methylation 1.23 (1.07, 1.41) 0.004** 1.28 (1.07, 1.54) 0.008 1.23 (1.11, 1.37) <.0001**
SULF2 2.72 (1.51, 4.91) 0.001** 2.97 (1.48, 5.95) 0.002** 2.73 (1.75, 4.25) <.0001**
p16 2.08 (1.01, 4.28) 0.048 1.66 (0.71, 3.89) 0.246 1.88 (1.09, 3.23) 0.023
JPH3 2.64 (1.43, 4.87) 0.002** 2.70 (0.96, 7.59) 0.059 2.66 (1.58, 4.48) <.0001**
PCDH20 1.68 (0.94, 2.98) 0.079 2.29 (1.15, 4.53) 0.018 1.89 (1.22, 2.93) 0.004**
Females LSC n = 673 PLuSS n = 307 Combined n = 980
Exposure variable OR (95% CL) p value OR (95% CL) p value OR (95% CL) p value
Total methylation 1.04 (0.96, 1.14) 0.324 1.08 (0.93, 1.25) 0.322 1.05 (0.98, 1.13) 0.188
SULF2 1.41 (0.97, 2.05) 0.074 1.72 (0.96, 3.07) 0.066 1.47 (1.07, 2.01) 0.016
p16 1.25 (0.79, 1.99) 0.342 1.76 (0.91, 3.40) 0.091 1.41 (0.97, 2.05) 0.073
JPH3 1.07 (0.71, 1.62) 0.748 1.20 (0.42, 3.39) 0.736 1.10 (0.75, 1.62) 0.634
PCDH20 1.33 (0.92, 1.93) 0.126 1.35 (0.72, 2.52) 0.346 1.34 (0.97, 1.83) 0.073
Each row represents a separate adjusted model.
*Additional adjustors include age, education, COPD, current smoking, pack years, and cohort (for combined analysis); CMH as outcome.
**Bonferroni adjusted significance threshold is p < 0.0042.
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effect sizes in current smokers (Table 5). Sex and smoking
stratified analysis of the combined cohorts (combined to
ensure adequate sample size for analysis) (Table 6) re-
vealed that the strongest associations between methyla-
tion and CMH were observed in male former smokers,
with odds ratios for the individual genes ranging from
2.55 to 4.34. Despite 2-3-fold greater number of female
participants in the LSC and PLuSS, only SULF-2 methy-
lation was associated with CMH in females from the
combined cohorts.Table 5 Odds ratios for CMH in adjusted* analyses of current
LSC former smokers n = 406 PLuSS for
Exposure variable OR (95% CL) p value OR (
Total methylation 1.13 (1.01, 1.26) 0.034 1.36 (
SULF2 1.96 (1.17, 3.29) 0.011 3.64 (
p16 2.06 (1.13, 3.76) 0.018 1.53 (
JPH3 1.79 (1.04, 3.09) 0.037 2.76 (
PCDH20 1.9 (1.13, 3.18) 0.015 1.15 (
LSC current smokers n = 494 PLuSS cu
Exposure variable OR (95% CL) p value OR (
Total methylation 1.07 (0.97, 1.17) 0.18 1.07 (
SULF2 1.53 (1.03, 2.28) 0.036 1.82 (
p16 1.15 (0.70, 1.89) 0.578 1.83 (
JPH3 1.3 (0.84, 1.99) 0.237 1.16 (
PCDH20 1.17 (0.79, 1.72) 0.433 1.98 (
Each row represents a separate adjusted model.
*Additional adjustors include age, sex, education, COPD, pack years, and cohort (for
**Bonferroni adjusted significance threshold is p < 0.0042.Sputum methylation is a sensitive and specific predictor
of CMH in male former smokers
Receiver operator characteristic (ROC) curves were
generated to assess the sensitivity and specificity of lo-
gistic regression models for discriminating CMH. Prior
to generating ROC curves, modeling was performed to
assess all combinations of predictors, including all 11
genes and covariates. The Akaike information content
(AICc) [25] was used to select the models with an optimal
trade-off between accuracy and complexity. Independently
in both the LSC and the PLuSS, the best-fitting model wasand former smokers
mer smokers n = 155 Combined former smokers n = 561
95% CL) p value OR (95% CL) p value
1.10, 1.67) 0.004** 1.18 (1.07, 1.30) 0.001**
1.51, 8.77) 0.004** 2.30 (1.47, 3.59) <.0001**
0.59, 3.95) 0.377 1.92 (1.16, 3.17) 0.012
0.99, 7.71) 0.053 2.02 (1.25, 3.26) 0.004**
0.46, 2.90) 0.768 1.67 (1.07, 2.61) 0.024
rrent smokers n = 335 Combined current smokers n = 829
95% CL) p value OR (95% CL) p value
0.94, 1.23) 0.303 1.07 (0.99, 1.15) 0.106
1.09, 3.04) 0.022 1.60 (1.17, 2.19) 0.003**
0.98, 3.41) 0.057 1.39 (0.95, 2.05) 0.094
0.42, 3.19) 0.779 1.29 (0.87, 1.91) 0.200
1.16, 3.36) 0.012 1.39 (1.02, 1.90) 0.039
combined analysis); CMH as outcome.
Table 6 Odds ratios for CMH in sex stratified adjusted* analyses of current and former smokers
Males Current smokers n = 269 Former smokers n = 139
Exposure variable OR (95% CL) p value OR (95% CL) p value
Total methylation 1.13 (0.99, 1.30) 0.076 1.39 (1.16, 1.67) <.0001**
SULF2 2.52 (1.47, 4.32) 0.001** 3.65 (1.59, 8.37) 0.002**
p16 1.36 (0.69, 2.67) 0.378 3.69 (1.42, 9.60) 0.007
JPH3 1.97 (1.02, 3.79) 0.043 4.34 (1.74, 10.79) 0.002**
PCDH20 1.71 (1.02, 2.86) 0.043 2.55 (1.11, 5.83) 0.027
Females Current smokers n = 560 Former smokers n = 410
Exposure variable OR (95% CL) p value OR (95% CL) p value
Total methylation 1.02 (0.93, 1.12) 0.617 1.10 (0.97, 1.24) 0.142
SULF2 1.27 (0.86, 1.88) 0.221 1.92 (1.12, 3.29) 0.019
p16 1.34 (0.83, 2.16) 0.230 1.52 (0.83, 2.80) 0.178
JPH3 0.94 (0.57, 1.56) 0.817 1.40 (0.77, 2.55) 0.272
PCDH20 1.28 (0.87, 1.89) 0.217 1.40 (0.81, 2.42) 0.226
Each row represents a separate adjusted model.
Analysis performed on combined cohorts.
*Additional adjustors include age, education, COPD, pack years, and cohort; CMH as outcome.
**Bonferroni adjusted significance threshold is p < 0.0042.
Figure 1 ROC curves comparing the sensitivity and specificity
of 3- and 11-gene methylation panels for classifying CMH. ROC
curves were generated by applying logistic regression models to
male former smokers (n = 139) from the combined PLuSS and LSC.
The covariates included age, pack years, education, and COPD. AUC
is indicated in parentheses.
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predictors, as well as age, pack years, education, and
COPD (data not shown). Therefore, using the combined
sample from the LSC and PLuSS, ROC curves were gener-
ated using the 3-gene model, the full 11-gene model, and
covariates-only model in male former smokers (Figure 1).
Likelihood ratio tests confirmed that both the 3-gene and
11-gene models are significantly more discriminative than
the covariates only model (p = 0.0002 and p = 0.002, re-
spectively); however, the 3- and 11-gene models were not
significantly different from each other (p = 0.29). Areas
under the curve (AUC) were 0.74 and 0.80 for the 3- and
11-gene models, respectively, while the AUC was 0.55 for
the covariates only model. Although sample sizes were
small in cohort-stratified analyses of male former smokers,
these analyses demonstrate that the increased discrimina-
tive power of the 3-gene model is observed in two inde-
pendent cohorts (Additional file 1: Figure S1).
Discussion
This study demonstrates a significant association be-
tween CMH and prevalence of promoter methylation in
sputum of lung cancer risk genes in two geographically
distinct cohorts. This association was especially strong
in males and in former smokers, and SULF2 was the
most consistently associated gene. Importantly, the over-
all association between CMH and methylation, and the
specific effects of sex and smoking status, were observed
independently in both cohorts. Combining the two co-
horts strengthened the statistical significance of these as-
sociations. The central finding of our study is that male
former smokers with unresolved CMH may be at an
increased risk of lung cancer. Given that 50% of personsdiagnosed with lung cancer are former smokers, pro-
spective studies evaluating the methylation status of
former smokers with CMH who subsequently develop
lung cancer are needed [26].
The eleven genes examined in this study were selected
based on prior evidence that they are associated with
lung cancer risk [17,18]. Therefore, increased prevalence
of methylation of these genes may predict lung cancer
among subjects with CMH. These gene promoters have
all been shown to be methylated in tumors [27,28], and
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cerous epigenetic changes in the aerodigestive tract of
smokers [17,29]. This hypothesis is supported by the ob-
servation that the methylation prevalence of these gene
promoters increases as the time to lung cancer diagnosis
decreases [17]. Mounting evidence indicates that these
changes are causal for tumor initiation [30-33].
The association between methylation and CMH was
markedly stronger in males than in females (Table 4).
Univariate analysis of males and females in both cohorts
(Additional file 1: Tables S3 and S4) reveals that females
with CMH are significantly younger than female controls
in the LSC; however this was not true in the PLuSS.
Additionally age was a covariate in all adjusted analyses
and thus is unlikely to account for the lack of association
between methylation and CMH in females. This appar-
ent protective mechanism in females warrants further
study. The association between methylation and CMH
was also stronger in former than in current smokers
(Table 5). The increase in effect size in former smokers
may be due to several reasons: (1) the CMH phenotype
in former smokers may not be confounded by cough
and phlegm caused by irritation due to current smoking;
(2) in susceptible smokers, CMH that persists in spite of
smoking cessation may represent a phenotype with a
more distinct molecular pathology; (3) The association
between CMH and gene promoter methylation may be
stronger with age. In the LSC and PLuSS cohorts, former
smokers were significantly older than current smokers
(mean age difference 4.2 years, data not shown). This age
difference between former and current smokers also likely
explains the puzzling observation that current smokers
have lower overall methylation compared to former
smokers (Additional file 1: Table S2); current smokers are
younger, and younger age is associated with less total
methylation in these lung cancer risk genes.
Numerous studies have demonstrated that prior CMH
significantly increases the risk for later development of
lung cancer (reviewed in [15,16]). Assessment of the la-
tency period between diagnosis of CMH and diagnosis
of lung cancer has shown that this risk increases with
time since diagnosis of CMH [34]. In one study [34], the
odds ratio nearly quadrupled at latency >15 years com-
pared to latency 1–5 years. Importantly, this suggests
that CMH may serve as a precursor to lung carcinogen-
esis [34]. We hypothesize that the increased prevalence
for methylation of the lung cancer risk genes seen in this
study may help explain the epidemiological link between
CMH and lung cancer. Further studies are needed to esta-
blish a direct link between gene methylation and lung can-
cer. Interestingly, while SULF2, p16, JPH3, and PCDH20 all
demonstrate evidence for association with CMH in the
current study, a previous study determined that GATA4
promoter methylation was associated with airflowobstruction [35]. These findings suggest that major differ-
ences exist in the genes affected by aberrant promoter
methylation in distinct COPD sub-phenotypes. This is
consistent with the major pathophysiological differences
that underlie emphysema and chronic mucous hyperse-
cretion [36], and suggests the role basal cell hyperplasia
may play in development of lung cancer [37].
Of the 11 genes analyzed, SULF2 demonstrated the
strongest association with CMH. SULF-2 is an extracellular
enzyme that catalyzes the hydrolysis of 6-O-sulfo groups
from heparan sulfate polysaccharides [38-40]. Heparan sul-
fate proteoglycans (HSPGs) are widely distributed on cell
membranes and the extracellular matrix, and serve as core-
ceptors for many growth factors and cytokines [41] and
the position of 6-O sulfates is of particular importance for
ligand binding [38-40]. Epigenetic inactivation of SULF2,
either by siRNA treatment or promoter methylation, acti-
vates numerous type I interferon (IFN)-inducible genes
[42]. It was proposed that silencing of SULF2 prevents the
removal of sulfate groups from IFN-binding sites, which
may preserve either the binding affinity or bioavailability of
interferons leading to increased transcription of multiple
IFN-inducible genes [42]. It is plausible that CMH, caused
by metaplastic mucous cells that are sustained due to dys-
regulated cell death mechanisms that involve IFN signaling
[43-45], creates an inflammatory milieu which causes
methylation of SULF2. In turn, the type 1 interferon
response induced by methylation of SULF2 may help to
perpetuate the inflammation associated with CMH.
This is the first report of epigenetic changes in the
airways of individuals with CMH. Strengths of the study
include the use of the large, well-characterized LSC for the
initial phase of study and excellent replication of all main
findings in the geographically distinct PLuSS. We chose the
standard definition for chronic bronchitis in the LSC and a
definition that most closely captured the standard clinical
definition of chronic bronchitis in the PLuSS. While the
differences in questionnaires used to define CMH could be
considered a limitation in the study, the definition for
CMH was applied to PLuSS subjects prior to any data ana-
lysis and was not subsequently modified. We propose that
this approach improves the rigor of our validation. Replica-
tion of these findings supports the robustness of these
markers for CMH and suggests that they are useful in de-
fining a subset of subjects with CMH who could benefit
from computed tomography (CT) screening for lung can-
cer [46]. Indeed, low cost, gene-specific methylation screen-
ing assays could be incorporated into clinical practices for
patients suspected to be at risk for lung cancer.
Conclusions
Especially male former smokers with persistent chronic
mucous hypersecretion have markedly increased promoter
methylation of lung cancer risk genes in cell obtained by
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http://respiratory-research.com/content/15/1/2sputum collection. These smokers may be at increased
risk of lung cancer and may benefit from further tests for
lung cancer, such as CT screening.
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